Home › Glioma › Illinois › Chicago

Glioma clinical trials in Chicago, IL

13 studies for Glioma are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

RecruitingPhase 1/2

University of Chicago Comprehensive Cancer Center, Chicago

12 Months – 21 Years · All sexes · Updated Oct 1, 2026 · NCT05099003

Targeted Pediatric High-Grade Glioma Therapy

RecruitingObservational study

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379

Study of Olutasidenib and Temozolomide in HGG

RecruitingPhase 2

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

RecruitingPhase 3

University of Chicago, Chicago

Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

RecruitingPhase 2

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

RecruitingPhase 1

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Ages 1 to 25 · All sexes · Updated Aug 18, 2026 · NCT04485559

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

RecruitingPhase 1/2

Research Site, Chicago

Ages 18 to 130 · All sexes · Updated Aug 12, 2026 · NCT05417594

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

RecruitingPhase 1

Northwestern Medicine, Chicago

Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07464925

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

RecruitingPhase 1/2

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Ages 1 to 26 · All sexes · Updated Jul 10, 2026 · NCT06712875

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

RecruitingEarly phase 1Healthy volunteers welcome

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

RecruitingPhase 2

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

RecruitingPhase 1/2

Northwestern Memorial Hospital, Chicago

Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06810544

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

RecruitingPhase 1

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

12 Months – 18 Years · All sexes · Updated Mar 17, 2026 · NCT04943848

Glioma trials in other cities

Other studies in Chicago

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.